PLCG1 (Phospholipase C, Gamma 1)

2014-02-01   Rebeca Manso 

Pathology Department, Fundacion Conchita Rabago, IIS Fundacion Jimenez Diaz, E-28040 Madrid, Spain


Atlas Image
Figure 1. Schematic diagram of PLCG1 location on chromosome 20. PLCG1 localizes to chromosome 20q12, which is represented graphically. PLCG1 gene spans 38.762 kb on the genomic DNA.



The PLCG1 gene spans 38.762 kb on the genomic DNA. The gene includes 32 exons.


There are two transcript variants: 5205 bp (isoform a) and 5202 bp (isoform b).


Atlas Image
Figure 2. Schematic representation of the domains of PLCG1. The protein contains eight domains, four of which are unique to PLCG family. The PLCG specific array of domains, comprising a "split" PH domain flanking two tandem SH2 domains and one SH3 domain, is inserted between the two halves (X and Y) of the TIM-barrel catalytic domain. Several other domains including two PH domains, one C2 domain and one EF hand motifs. The numering of the amino acid residues is for human PLCG1 (Suh et al., 2008; Bunney and Katan, 2011).


The PLCG1 protein encodes two alternative isoforms: variant a (P19174-1)-1290 amino acids, 148.53 Da; variant b (P19174-2)-1291 amino acids, 148.66 Da.


PLCG1 is expressed ubiquitously, especially in the brain, thymus, intestine and lungs. Additionally, PLCG1 is overexpressed in numerous cancer types such as human colorectal cancer (Noh et al., 1994), breast carcinoma (Arteaga et al., 1991), prostate carcinoma (Peak et al., 2008), familial adenomatous polyposis (Park et al., 1994) and human skins under hypeproliferative conditions (Nanney et al., 1992).


PLCG1 localizes predominantly in the plasmatic membrane, cytoplasm and nucleus.


PLCG1 is a protein involved in multiple cellular processes. A potent inhibitor of PLCG1 (U-73122) has been reported to inhibit PLCG1-dependent processes in cells (Smith et al., 1990; Thompson et al., 1991; Thomas et al., 2003; Li et al., 2005). The inhibition of PLCG1 may be an important mechanism for an antiproliferative effect on the human cancer cells.
Role in the production of the second messenger molecules: PLCG1 mediates the production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) from the hydrolysis of phosphatidynositol-4,5-bisphosphate (PIP2) (Williams et al., 1996). These second messengers are essential for T cell activation (Lin et al., 2001).
Role in cellular proliferation: PLCG1 is associated with tumor development, and it is overexpressed in some tumors (Shin et al., 2007). This overexpression stimulates MMP-3 expression. PLCG1 is required for metastasis development (Sala et al., 2008).
Role in angiogenesis: PLCG1 plays an important role in angiogenesis (Husain et al., 2010). PLCG1 is activated by vascular endothelial growth factor receptor-2 (VEGFR-2) in endothelial cells (Singh et al., 2007) and in neoplastic Barretts cells (Zhang et al., 2013).
Role in the regulation of intracellular signaling: PLCG1 plays a role in mediating T-cell activities downstream of TCR activity. PLCG1 can be activated by receptor tyrosine kinases: EGFR (Nishibe et al., 1990; Wu et al., 2009), PDGFR (Larose et al., 1993), FGFR (Peters et al., 1992), NGFR (Middlemas et al., 1994) and HGFR (Davies et al., 2008). PLCG1 is a molecule associate with lipid rafts, it translocates from the cytosol to lipid rafts during TCR signaling (Verí et al., 2001).
Role in the mobilization of Ca2+: this process is to activate phosphatase calcineurin, which in turn dephosphorylates and activates NFAT (Rao et al., 1997). Truncation of the N terminus of Vav1 is accompanied by a decrease in PLCG1 phosphorylation and this inhibits calcium mobilization (Knyazhitsky et al., 2012).
Role in cytoskeleton: PLCG1 plays a role in actin reorganization (Pei et al., 1996; Wells, 2000; Wang et al., 2007; Li et al., 2009).
Role in adhesion and migration: PLCG1 mediates cell adhesion and migration through an undefined mechanism (Wang et al., 2007; Crooke et al., 2009). PLCG1 plays a role in integrin-mediated cell motility processes (Jones et al., 2005).
Role in apoptosis: PLCG1 is proteolytically cleaved by group II caspases especially by caspase-3 and caspase-7 during apoptosis. This results in the loss of receptor-mediated tyrosine phosphorylation (Bae et al., 2000). PLCG1 plays a protective role in H2O2-induced PC12 cells death (Yuan et al., 2009). The Fas-mediated apoptosis requires endoplasmic reticulum-mediated calcium release in a mechanism dependent on PLCG1 activation (Wozniak et al., 2006).
Role in transformation: PLCG1 interacts with Middle tumor antigen (MT). The tyrosine phosphorylation level of PLCG1 is elevated in cells expressing wild type MT but not in cells expressing Tyr322→Phe MT (Su et al., 1995).
Role in autoimmune symptoms: PLCG1 deficiency impairs the development and function regulatory cells (FoxP3+), causing inflammatory/autoimmune symptoms (Fu et al., 2010).


The protein contains eight domains, four of which are unique to PLCG family (Suh et al., 2008). The PLCG specific array of domains, comprising a "split" PH domain flanking two tandem SH2 domains and one SH3 domain, is inserted between the two halves (X and Y) of the TIM-barrel catalytic domain (Bunney and Katan, 2011). Several other domains including two PH domains, one C2 domain and one EF hand motifs (Suh et al., 2008).



99 mutations have been described in the PLCG1 gene, according to the Catalogue of Somatic Mutations in Cancer (COSMIC) database. De novo mutation has been described in patients with Cutaneous T-cell lymphoma (CTCL): S345F (10/53 analyzed CTCL samples, 19%) (Vaqué et al., 2014).

Implicated in

Entity name
Breast cancer
Overexpression of PLCG1 is a marker of development of metastases in breast cancer (Lattanzio et al., 2013). Loss of PLCG1 in part mimicked the effect of miR-200b/miR-c/miR-429 overexpression in viability, apoptosis and EGF-driven cell invasion of breast cancer cells (Uhlmann et al., 2010).
Entity name
Colorectal cancer
PLCG1 has a potencial role in colon cancer (Nomoto et al., 1995; Li et al., 2005; Reid et al., 2009). The activity of PLCG1 is reduced in STAT3 Y705F mutant colorectal cancer cells (Zhang et al., 2011), it shows that there is crosstalk between STAT3 and PLCG1 signaling pathways.
Entity name
Prostate carcinoma
PLCG1 has a role in the regulation of PC3LN3 (human prostate carcinoma cells) cell adhesion that appears to be independent of its effects on tumour cell chemotactic migration and spreading in response to extracellular matrix (Peak et al., 2008).
Entity name
Gastric cancer
PLCG1 plays a role in RhoGDI2-mediated cisplatin resistance and cell invasion in gastric cancer (Cho et al., 2011).
Entity name
Squamous cell carcinoma (SCC)
PLCG1 is a downstream target of EGFR signaling. PLCG1 is required for EGFR-induced SCC cell mitogenesis (Xie et al., 2010).
Entity name
Oral potentially malignant lesions (OPLs)
PLCG1 is highly expressed in oral cancer lesions compared with normal oral mucosa (Ma et al., 2013).
Entity name
Esophageal adenocarcinoma
PLCG1-PKC-ERK pathway promotes proliferation and it is activated by VEGFR-2 in neoplastic Barretts cells (Zhang et al., 2013).
Entity name
Pheochromocytoma (PC)
PLCG1 plays a role in apoptosis of PC12 cells induced by H2O2 (Yuan et al., 2009).
Entity name
PLCG1 is associated with lifetime and overall survival in glioblastoma and it can be a novel biomarker of this desease (Serão et al., 2011).
Entity name
The mutation in the catalytic domain of PLCG1 (S345F) is detection in patients with CTCL. PLCG1 mutants induced enhanced PLCG1 downstream signaling towards NFAT activation (Vaqué et al., 2014).
Entity name
Brain disorders
Jang et al., 2013.
PLCG1 is highly expressed in brain. Abnormal expression and activation of PLCG1 appears in epilepsy (He et al., 2010), bipolar disorder (Løvlie et al., 2001), depression (Dwivedi et al., 2005), Huntingtons disease (Giralt et al., 2009) and Alzheimers disease (Shimohama et al., 1995).
Entity name
Myocardial dysfunction in sepsis
PLCG1 signaling induces cardiac TNF-alpha expression and myocardial dysfunction during Lipopolysaccharide (LPS) stimulation. Inhibition of PLCG1 decreased cardiac TNF-alpha expression and LPS-induced myocardial dysfunction was also attenuated (Peng et al., 2008).


Pubmed IDLast YearTitleAuthors
16837011991Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas.Arteaga CL et al
108349292000Proteolytic cleavage of phospholipase C-gamma1 during apoptosis in Molt-4 cells.Bae SS et al
208704102011PLC regulation: emerging pictures for molecular mechanisms.Bunney TD et al
219865282011PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.Cho HJ et al
193797312009PLC-gamma1 regulates fibronectin assembly and cell aggregation.Crooke CE et al
183671082008Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells.Davies G et al
211496022011Beta-catenin inhibits T cell activation by selective interference with linker for activation of T cells-phospholipase C-γ1 phosphorylation.Driessens G et al
155364952005Single and repeated stress-induced modulation of phospholipase C catalytic activity and expression: role in LH behavior.Dwivedi Y et al
201239622010Phospholipase C{gamma}1 is essential for T cell development, activation, and tolerance.Fu G et al
191213722009Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression.Giralt A et al
204450442010Disruption of TrkB-mediated phospholipase Cgamma signaling inhibits limbic epileptogenesis.He XP et al
205922362010Role of c-Cbl-dependent regulation of phospholipase Cgamma1 activation in experimental choroidal neovascularization.Husain D et al
230635872013Phospholipase C-γ1 involved in brain disorders.Jang HJ et al
159443972005PLCgamma1 is essential for early events in integrin signalling required for cell motility.Jones NP et al
110486392000The mechanism of phospholipase C-gamma1 regulation.Kim MJ et al
224743312012Vav1 oncogenic mutation inhibits T cell receptor-induced calcium mobilization through inhibition of phospholipase Cγ1 activation.Knyazhitsky M et al
76897241993Identification of residues in the beta platelet-derived growth factor receptor that confer specificity for binding to phospholipase C-gamma 1.Larose L et al
228472942013Overexpression of activated phospholipase Cγ1 is a risk factor for distant metastases in T1-T2, N0 breast cancer patients undergoing adjuvant chemotherapy.Lattanzio R et al
192648422009PLC-gamma1 and Rac1 coregulate EGF-induced cytoskeleton remodeling and cell migration.Li S et al
159966872005NF-kappaB and Hsp70 are involved in the phospholipase Cgamma1 signaling pathway in colorectal cancer cells.Li X et al
111481242001T cell receptor signalling.Lin J et al
114096992001The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism.Løvlie R et al
226719752013Phospholipase C-γ1 expression correlated with cancer progression of potentially malignant oral lesions.Ma LW et al
81065271994Identification of TrkB autophosphorylation sites and evidence that phospholipase C-gamma 1 is a substrate of the TrkB receptor.Middlemas DS et al
15153691992Altered distribution of phospholipase C-gamma 1 in benign hyperproliferative epidermal diseases.Nanney LB et al
21533021990Selectivity of phospholipase C phosphorylation by the epidermal growth factor receptor, the insulin receptor, and their cytoplasmic domains.Nishibe S et al
82754351994Elevated content of phospholipase C-gamma 1 in colorectal cancer tissues.Noh DY et al
78933681995Expression of phospholipases gamma 1, beta 1, and delta 1 in primary human colon carcinomas and colon carcinoma cell lines.Nomoto K et al
81741331994Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis.Park JG et al
180379572008Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion.Peak JC et al
89413571996Phospholipase C-gamma 1 binds to actin-cytoskeleton via its C-terminal SH2 domain in vitro.Pei Z et al
180791032008Disruption of phospholipase Cgamma1 signalling attenuates cardiac tumor necrosis factor-alpha expression and improves myocardial function during endotoxemia.Peng T et al
13796971992Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis.Peters KG et al
91437051997Transcription factors of the NFAT family: regulation and function.Rao A et al
170157222006Differential and nonredundant roles of phospholipase Cgamma2 and phospholipase Cgamma1 in the terminal maturation of NK cells.Regunathan J et al
196728742009Integrative approach for prioritizing cancer genes in sporadic colon cancer.Reid JF et al
190748862008Phospholipase Cgamma1 is required for metastasis development and progression.Sala G et al
216499002011Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival.Serão NV et al
85370141995Differential involvement of phospholipase C isozymes in Alzheimer's disease.Shimohama S et al
171969352007Phospholipase Cgamma1 stimulates transcriptional activation of the matrix metalloproteinase-3 gene via the protein kinase C/Raf/ERK cascade.Shin SY et al
173722302007A critical role for the E3-ligase activity of c-Cbl in VEGFR-2-mediated PLCgamma1 activation and angiogenesis.Singh AJ et al
23386541990Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness.Smith RJ et al
77594721995Association of Polyomavirus middle tumor antigen with phospholipase C-gamma 1.Su W et al
185935252008Multiple roles of phosphoinositide-specific phospholipase C isozymes.Suh PG et al
145004052003Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.Thomas SM et al
16608861991The aminosteroid U-73122 inhibits muscarinic receptor sequestration and phosphoinositide hydrolysis in SK-N-SH neuroblastoma cells. A role for Gp in receptor compartmentation.Thompson AK et al
205140232010miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer.Uhlmann S et al
244975362014PLCG1 mutations in cutaneous T-cell lymphomas.Vaqué JP et al
115648772001Membrane raft-dependent regulation of phospholipase Cgamma-1 activation in T lymphocytes.Verí MC et al
172298142007Obligatory role for phospholipase C-gamma(1) in villin-induced epithelial cell migration.Wang Y et al
105476682000Tumor invasion: role of growth factor-induced cell motility.Wells A et al
89949651996Structural views of phosphoinositide-specific phospholipase C: signalling the way ahead.Williams RL et al
171302902006Requirement of biphasic calcium release from the endoplasmic reticulum for Fas-mediated apoptosis.Wozniak AL et al
196055472009EGFR-PLCgamma1 signaling mediates high glucose-induced PKCbeta1-Akt activation and collagen I upregulation in mesangial cells.Wu D et al
205106732010Phospholipase C-gamma1 is required for the epidermal growth factor receptor-induced squamous cell carcinoma cell mitogenesis.Xie Z et al
196575632009Hydrogen peroxide induces the activation of the phospholipase C-gamma1 survival pathway in PC12 cells: protective role in apoptosis.Yuan W et al
218409322011Cross-talk between phospho-STAT3 and PLCγ1 plays a critical role in colorectal tumorigenesis.Zhang P et al
241204732014Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.Zhang Q et al

Other Information

Locus ID:

NCBI: 5335
MIM: 172420
HGNC: 9065
Ensembl: ENSG00000124181


dbSNP: 5335
ClinVar: 5335
TCGA: ENSG00000124181


Gene IDTranscript IDUniprot

Expression (GTEx)



PathwaySourceExternal ID
Inositol phosphate metabolismKEGGko00562
ErbB signaling pathwayKEGGko04012
Calcium signaling pathwayKEGGko04020
Phosphatidylinositol signaling systemKEGGko04070
Axon guidanceKEGGko04360
VEGF signaling pathwayKEGGko04370
Natural killer cell mediated cytotoxicityKEGGko04650
T cell receptor signaling pathwayKEGGko04660
Fc epsilon RI signaling pathwayKEGGko04664
Leukocyte transendothelial migrationKEGGko04670
Vibrio cholerae infectionKEGGko05110
Epithelial cell signaling in Helicobacter pylori infectionKEGGko05120
Non-small cell lung cancerKEGGko05223
Inositol phosphate metabolismKEGGhsa00562
ErbB signaling pathwayKEGGhsa04012
Calcium signaling pathwayKEGGhsa04020
Phosphatidylinositol signaling systemKEGGhsa04070
Axon guidanceKEGGhsa04360
VEGF signaling pathwayKEGGhsa04370
Natural killer cell mediated cytotoxicityKEGGhsa04650
T cell receptor signaling pathwayKEGGhsa04660
Fc epsilon RI signaling pathwayKEGGhsa04664
Leukocyte transendothelial migrationKEGGhsa04670
Vibrio cholerae infectionKEGGhsa05110
Epithelial cell signaling in Helicobacter pylori infectionKEGGhsa05120
Pathways in cancerKEGGhsa05200
Non-small cell lung cancerKEGGhsa05223
Neurotrophin signaling pathwayKEGGko04722
Neurotrophin signaling pathwayKEGGhsa04722
Fc gamma R-mediated phagocytosisKEGGko04666
Fc gamma R-mediated phagocytosisKEGGhsa04666
Metabolic pathwaysKEGGhsa01100
Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4KEGGhsa_M00130
Inositol phosphate metabolism, PI=> PIP2 => Ins(1,4,5)P3 => Ins(1,3,4,5)P4KEGGM00130
Epstein-Barr virus infectionKEGGhsa05169
Epstein-Barr virus infectionKEGGko05169
NF-kappa B signaling pathwayKEGGhsa04064
NF-kappa B signaling pathwayKEGGko04064
HIF-1 signaling pathwayKEGGhsa04066
Proteoglycans in cancerKEGGhsa05205
Proteoglycans in cancerKEGGko05205
MicroRNAs in cancerKEGGhsa05206
MicroRNAs in cancerKEGGko05206
Ras signaling pathwayKEGGhsa04014
Rap1 signaling pathwayKEGGhsa04015
Rap1 signaling pathwayKEGGko04015
Thyroid hormone signaling pathwayKEGGhsa04919
Inflammatory mediator regulation of TRP channelsKEGGhsa04750
Inflammatory mediator regulation of TRP channelsKEGGko04750
Choline metabolism in cancerKEGGhsa05231
Choline metabolism in cancerKEGGko05231
Diseases of signal transductionREACTOMER-HSA-5663202
Signaling by EGFR in CancerREACTOMER-HSA-1643713
Signaling by Ligand-Responsive EGFR Variants in CancerREACTOMER-HSA-5637815
Constitutive Signaling by Ligand-Responsive EGFR Cancer VariantsREACTOMER-HSA-1236382
Signaling by EGFRvIII in CancerREACTOMER-HSA-5637812
Constitutive Signaling by EGFRvIIIREACTOMER-HSA-5637810
Signaling by FGFR in diseaseREACTOMER-HSA-1226099
Signaling by FGFR1 in diseaseREACTOMER-HSA-5655302
Signaling by FGFR2 in diseaseREACTOMER-HSA-5655253
Signaling by FGFR3 in diseaseREACTOMER-HSA-5655332
Signaling by FGFR4 in diseaseREACTOMER-HSA-5655291
Immune SystemREACTOMER-HSA-168256
Adaptive Immune SystemREACTOMER-HSA-1280218
TCR signalingREACTOMER-HSA-202403
Generation of second messenger moleculesREACTOMER-HSA-202433
Signaling by the B Cell Receptor (BCR)REACTOMER-HSA-983705
Antigen activates B Cell Receptor (BCR) leading to generation of second messengersREACTOMER-HSA-983695
Innate Immune SystemREACTOMER-HSA-168249
Fcgamma receptor (FCGR) dependent phagocytosisREACTOMER-HSA-2029480
Role of phospholipids in phagocytosisREACTOMER-HSA-2029485
DAP12 interactionsREACTOMER-HSA-2172127
DAP12 signalingREACTOMER-HSA-2424491
DAG and IP3 signalingREACTOMER-HSA-1489509
Fc epsilon receptor (FCERI) signalingREACTOMER-HSA-2454202
FCERI mediated MAPK activationREACTOMER-HSA-2871796
FCERI mediated Ca+2 mobilizationREACTOMER-HSA-2871809
Cytokine Signaling in Immune systemREACTOMER-HSA-1280215
Interferon SignalingREACTOMER-HSA-913531
Antiviral mechanism by IFN-stimulated genesREACTOMER-HSA-1169410
ISG15 antiviral mechanismREACTOMER-HSA-1169408
Cell surface interactions at the vascular wallREACTOMER-HSA-202733
PECAM1 interactionsREACTOMER-HSA-210990
Signal TransductionREACTOMER-HSA-162582
Signaling by EGFRREACTOMER-HSA-177929
EGFR interacts with phospholipase C-gammaREACTOMER-HSA-212718
Signaling by FGFRREACTOMER-HSA-190236
Signaling by FGFR1REACTOMER-HSA-5654736
Downstream signaling of activated FGFR1REACTOMER-HSA-5654687
Phospholipase C-mediated cascade: FGFR1REACTOMER-HSA-5654219
Signaling by FGFR2REACTOMER-HSA-5654738
Downstream signaling of activated FGFR2REACTOMER-HSA-5654696
Phospholipase C-mediated cascade; FGFR2REACTOMER-HSA-5654221
Signaling by FGFR3REACTOMER-HSA-5654741
Downstream signaling of activated FGFR3REACTOMER-HSA-5654708
Phospholipase C-mediated cascade; FGFR3REACTOMER-HSA-5654227
Signaling by FGFR4REACTOMER-HSA-5654743
Downstream signaling of activated FGFR4REACTOMER-HSA-5654716
Phospholipase C-mediated cascade; FGFR4REACTOMER-HSA-5654228
Signalling by NGFREACTOMER-HSA-166520
NGF signalling via TRKA from the plasma membraneREACTOMER-HSA-187037
Signalling to ERKsREACTOMER-HSA-187687
Prolonged ERK activation eventsREACTOMER-HSA-169893
Frs2-mediated activationREACTOMER-HSA-170968
PLC-gamma1 signallingREACTOMER-HSA-167021
Signaling by PDGFREACTOMER-HSA-186797
Downstream signal transductionREACTOMER-HSA-186763
Signaling by VEGFREACTOMER-HSA-194138
VEGFR2 mediated cell proliferationREACTOMER-HSA-5218921
Signaling by ERBB2REACTOMER-HSA-1227986
PLCG1 events in ERBB2 signalingREACTOMER-HSA-1251932
Inositol phosphate metabolismREACTOMER-HSA-1483249
Synthesis of IP3 and IP4 in the cytosolREACTOMER-HSA-1855204
Developmental BiologyREACTOMER-HSA-1266738
Axon guidanceREACTOMER-HSA-422475
Netrin-1 signalingREACTOMER-HSA-373752
Role of second messengers in netrin-1 signalingREACTOMER-HSA-418890
Phospholipase D signaling pathwayKEGGko04072
Phospholipase D signaling pathwayKEGGhsa04072
AGE-RAGE signaling pathway in diabetic complicationsKEGGko04933
AGE-RAGE signaling pathway in diabetic complicationsKEGGhsa04933
Signaling by FGFR3 point mutants in cancerREACTOMER-HSA-8853338
EGFR tyrosine kinase inhibitor resistanceKEGGko01521
EGFR tyrosine kinase inhibitor resistanceKEGGhsa01521
RET signalingREACTOMER-HSA-8853659
Th1 and Th2 cell differentiationKEGGko04658
Th1 and Th2 cell differentiationKEGGhsa04658
Th17 cell differentiationKEGGko04659
Th17 cell differentiationKEGGhsa04659

Protein levels (Protein atlas)

Not detected


Entity IDNameTypeEvidenceAssociationPKPDPMIDs
PA451140propionic acid derivativesChemicalClinicalAnnotationassociatedPD26398624


Pubmed IDYearTitleCitations
128453322003Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1.133
182566832008A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.116
199131212009Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.85
246331572014Recurrent PTPRB and PLCG1 mutations in angiosarcoma.78
184673322008Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases.77
205140232010miR-200bc/429 cluster targets PLCgamma1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer.77
190180072008Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells.48
244975362014PLCG1 mutations in cutaneous T-cell lymphomas.47
170236582006Action of TFII-I outside the nucleus as an inhibitor of agonist-induced calcium entry.43
220222822011A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains.43


Rebeca Manso

PLCG1 (Phospholipase C, Gamma 1)

Atlas Genet Cytogenet Oncol Haematol. 2014-02-01

Online version: